Pharmaceutical compositions for the treatment of ocular...

Details Pharmaceutical compositions for the treatment of ocular... Pharmaceutical compositions for the treatment of ocular...

A - Human Necessities

61

K

A61K 31/5575 (2006.01) A61P 27/06 (2006.01)

Patent

CA 2356912

By combined administration of a non-FP receptor agonist type prostaglandin compound, for example isopropyl unoprostone, and a FP-receptor type prostaglandin compound, for example Latanoprost, the ocular hypotensive effect of the prostaglandin compounds is synergistically enhanced.

L'invention concerne l'utilisation simultanée d'un composé de prostaglandine du type agoniste de récepteur non FP (tel que l'isopropyl unoprostone) et d'un composé de prostaglandine du type agoniste de récepteur FP (tel que le latanoprost) pour provoquer un effet synergique accru de réduction de la tension oculaire.

Affiliated with

Also associated with

Rating

Pharmaceutical compositions for the treatment of ocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions for the treatment of ocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for the treatment of ocular... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1988658